
Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. (EPRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
eprx · pe ratio · data through Jun 8, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 1 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc.You EPRX | $204M | N/A | — | — |
Genfit S.A. GNFT | $446M | 119.75x | — | $0.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Eupraxia Pharmaceuticals Inc. (EPRX) measures how much investors pay for each dollar of the company's trailing earnings. EPRX's current PE ratio of N/A is calculated by dividing its stock price of $6.11 by its TTM earnings per share of —.
Frequently asked questions
EPRX pe ratio · 6 questionsEPRX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $6.11 and TTM EPS of —. Data sourced from Financial Modeling Prep via EPRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Eupraxia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08